SUMMARY Two patients with rheumatoid arthritis developed pancytopenia during treatment with azathioprine 100 mg daily. In one patient this side effect occurred after three weeks, in the other after eight weeks of treatment. Rapid fall of platelets in one patient necessitated platelet transfusion. In the other patient additional treatment with allopurinol was probably responsible for the toxic effect. Haematological side effects of azathioprine are discussed.
Azathioprine has been extensively used for more than 20 years in the treatment of patients with rheumatoid arthritis (RA) who are unresponsive or react with side effects to gold salts or Dpenicillamine, or both. At a dosage of 1-5-2-5 mg/kg/day the toxic reactions of azathioprine are moderate and limited mainly to gastrointestinal and mild haematological complications. '2 Pancytopenia in relation to this drug is a rare side effect. So far, 18 cases of pancvtopenia during azathioprine treatment used for a variety of diseases, given in different dosages and in combination with different other drugs, have been reported wor-Id wide.3 Detailed descriptions of these cases are mostly lacking.
We report two patients with rheumatoid arthritis who developed pancytopenia while receiving azathioprine 1(X) mg daily. In one patient platelet transfusion was necessary because of severe thrombocytopenia. The pancytopenia disappeared in both patients after azathioprine treatment was stopped. Leucopenia is the most frequent haematological complication of azathioprine treatment. In published reviews about this adverse drug reaction in patients with RA the incidence of leucopenia ranges from 11 to 14.5%.1 2 Agranulocytosis within one week of azathioprine administration is very rare and possibly an idiosyncratic reaction. Other haematological changes are thrombocytopenia, anaemia, and macrocytosis. Thrombocytopenia is an uncommon side effect reported in 0O8-4/8% of cases.' 2 It rarely develops without leucopenia. In our second patient isolated thrombocytopenia developed two weeks after restarting azathioprine. Pure red cell aplasia induced by azathioprine is a very rare adverse reaction. It reflects a selective toxic effect of azathioprine on erythropoiesis.67
Macrocytosis has been reported in transplant recipients and ascribed to interference with DNA synthesis.7-9 It is unrelated to the metabolism of folic acid or vitamin B12, or both. In our patients we could not find a significant alteration in the MCV. In the second patient a declining haemoglobin concentration occurred two weeks before the leucopenia and thrombocytopenia. When the negative result of the gastroscopy and the laboratory values are considered the anaemia appears to be related to azathioprine.
In the case of patient 1 the general practitioner had not brought to our notice the haematological changes (leucocytes 3-3x 109/l, platelets 123x i09/l) a week before she visited us. At that time we could have discontinued or diminished the dosage. An additional toxic effect of indomethacin on the bone marrow was unlikely because she had taken that drug for many years. In retrospect, owing to the absence of megakaryocytes from the bone marrow and the absence of antibodies to granulocytes and platelets, the indications for administering high dosage prednisone were debatable. As she had developed leucopenia and thrombocytopenia while taking D-penicillamine in the past she may have been predisposed to bone marrow suppression due to different drugs.
Pancvtopenia related to azathioprinie in RA 505
There are several reports of pancvtopenia due to the combination of azathioprine and allopurinol,'1 as occurred in patient 2. Azathioprine is rapidly converted to 6-mercaptopurine. The major metabolite of 6-mercaptopurine, 6 -thiouric acid, is excreted in the urine. The enzyme xanthine oxidase is responsible for this oxidation. Allopurinol inhibits this enzyme and so administration of azathioprine together with allopurinol gives rise to an increased 6-mercaptopurine blood concentration, which can induce bone marrow toxicitv. If it is necessary to administer both drugs it is advisable to reduce the usual dose of azathioprine by about 75%.' ? In patient 2 this rule was unfortunately not applied.
Finally, when azathioprine is prescribed, close clinical and laboratory controls are necessary. Increased toxicity due to additional drugs has to be considered. Fortunately, both these patients recovered completely from this rare but dangerous adverse reaction to azathioprine.
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